NeOnc Technologies Holdings Inc
NTHI
查看详细走势图
7.300USD
+0.290+4.14%
交易中 （美东）报价延迟15分钟
142.16M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+4.14%
5天
-28.50%
1月
+24.57%
6月
+71.56%
今年开始到现在
0.00%
1年
0.00%
查看详细走势图
TradingKey NeOnc Technologies Holdings Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
NeOnc Technologies Holdings Inc当前公司基本面数据相对健康，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名224/404位。机构持股占比非常高，中期看，股价处于下降通道。近一个月，市场表现很强，技术面评分较高，但很强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
NeOnc Technologies Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
0
位分析师
--
评级
0.000
目标均价
0.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
NeOnc Technologies Holdings Inc亮点
亮点风险
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
业绩高增长
公司营业收入稳步增长，连续3年增长315.00%
业绩增长期
公司处于发展阶段，最新年度总收入83.00K美元
利润高增长
公司净利润处于行业前列，最新年度总收入83.00K美元
估值合理
公司最新PE估值-2.69，处于3年历史合理位
机构加仓
最新机构持股1.61M股，环比增加44.32%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值140.91K
NeOnc Technologies Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
NeOnc Technologies Holdings Inc简介
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
公司代码NTHI
公司NeOnc Technologies Holdings Inc
CEOHeshmatpour (Amir F)
网址https://neonc.com/
常见问题
NeOnc Technologies Holdings Inc(NTHI)的当前股价是多少？
NeOnc Technologies Holdings Inc(NTHI)的当前股价是 7.300。
NeOnc Technologies Holdings Inc的股票代码是什么？
NeOnc Technologies Holdings Inc的股票代码是NTHI。
NeOnc Technologies Holdings Inc股票的52周最高点是多少？
NeOnc Technologies Holdings Inc股票的52周最高点是25.000。
NeOnc Technologies Holdings Inc股票的52周最低点是多少？
NeOnc Technologies Holdings Inc股票的52周最低点是3.200。
NeOnc Technologies Holdings Inc的市值是多少？
NeOnc Technologies Holdings Inc的市值是142.16M。
NeOnc Technologies Holdings Inc的净利润是多少？
NeOnc Technologies Holdings Inc的净利润为-11.90M。
现在NeOnc Technologies Holdings Inc(NTHI)的股票是买入、持有还是卖出？
根据分析师评级，NeOnc Technologies Holdings Inc(NTHI)的总体评级为--，目标价格为--。
NeOnc Technologies Holdings Inc(NTHI)股票的每股收益（EPS TTM）是多少
NeOnc Technologies Holdings Inc(NTHI)股票的每股收益（EPS TTM）是-2.602。
相关品种
